Amgen Inc.

Symbol: AMG.DE

XETRA

259.8

EUR

Market price today

  • 24.7658

    P/E Ratio

  • -6.3755

    PEG Ratio

  • 139.23B

    MRK Cap

  • 0.03%

    DIV Yield

Amgen Inc. (AMG-DE) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.70%

Operating Profit Margin

0.32%

Net Profit Margin

0.24%

Return on Assets

0.07%

Return on Equity

1.03%

Return on Capital Employed

0.12%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Robert A. Bradway
Full-time employees:26700
City:Thousand Oaks
Address:One Amgen Center Drive
IPO:2000-01-03
CIK:

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.700% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.321%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.238%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.069% return, is a testament to Amgen Inc.'s adeptness in optimizing resource deployment. Amgen Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.033%. Furthermore, the proficiency of Amgen Inc. in capital utilization is underscored by a remarkable 0.115% return on capital employed.

Stock Prices

Amgen Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $259.8, while its low point bottomed out at $252.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Amgen Inc.'s stock market.

Liquidity Ratios

Analyzing AMG.DE liquidity ratios reveals its financial health of the firm. The current ratio of 164.92% gauges short-term asset coverage for liabilities. The quick ratio (102.69%) assesses immediate liquidity, while the cash ratio (59.50%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio164.92%
Quick Ratio102.69%
Cash Ratio59.50%

Profitability Ratios

AMG.DE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 27.86% underscores its earnings before tax deductions. The effective tax rate stands at 14.49%, revealing its tax efficiency. The net income per EBT, 85.51%, and the EBT per EBIT, 86.69%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 32.14%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin27.86%
Effective Tax Rate14.49%
Net Income per EBT85.51%
EBT per EBIT86.69%
EBIT per Revenue32.14%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.65, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 354.95% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding103
Days of Inventory Outstanding411
Operating Cycle513.92
Days of Payables Outstanding69
Cash Conversion Cycle445
Receivables Turnover3.55
Payables Turnover5.32
Inventory Turnover0.89
Fixed Asset Turnover4.74
Asset Turnover0.29

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 15.83, and free cash flow per share, 13.76, depict cash generation on a per-share basis. The cash per share value, 20.46, showcases liquidity position. A payout ratio of 0.68 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.30, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share15.83
Free Cash Flow per Share13.76
Cash per Share20.46
Payout Ratio0.68
Operating Cash Flow Sales Ratio0.30
Free Cash Flow to Operating Cash Flow Ratio0.87
Cash Flow Coverage Ratio0.13
Short Term Coverage Ratio5.87
Capital Expenditure Coverage Ratio7.62
Dividend Paid and Capex Coverage Ratio1.49
Dividend Payout Ratio0.03

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 66.51%, highlights its total liabilities relative to assets. With a debt-equity ratio of 10.37, we discern the balance between debt and equity financing. The long-term debt to capitalization, 91.02%, and total debt to capitalization, 91.20%, ratios shed light on its capital structure. An interest coverage of 3.15 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio66.51%
Debt Equity Ratio10.37
Long Term Debt to Capitalization91.02%
Total Debt to Capitalization91.20%
Interest Coverage3.15
Cash Flow to Debt Ratio0.13
Company Equity Multiplier15.59

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 52.69, provides a glimpse into top-line earnings distributed across each share. Net income per share, 12.56, reflects the portion of profit attributed to each share. The book value per share, 11.65, represents the net asset value distributed per share, while the tangible book value per share, -84.18, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share52.69
Net Income Per Share12.56
Book Value Per Share11.65
Tangible Book Value Per Share-84.18
Shareholders Equity Per Share11.65
Interest Debt Per Share126.15
Capex Per Share-2.08

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 7.09%, indicates top-line expansion, while the gross profit growth, -0.89%, reveals profitability trends. EBIT growth, 48.02%, and operating income growth, 48.02%, offer insights into operational profitability progression. The net income growth, 2.52%, showcases bottom-line expansion, and the EPS growth, 3.12%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth7.09%
Gross Profit Growth-0.89%
EBIT Growth48.02%
Operating Income Growth48.02%
Net Income Growth2.52%
EPS Growth3.12%
EPS Diluted Growth3.14%
Weighted Average Shares Growth-0.56%
Weighted Average Shares Diluted Growth-0.55%
Dividends per Share Growth9.19%
Operating Cash Flow Growth-12.86%
Free Cash Flow Growth-16.23%
10-Year Revenue Growth per Share112.45%
5-Year Revenue Growth per Share46.67%
3-Year Revenue Growth per Share21.45%
10-Year Operating CF Growth per Share89.52%
5-Year Operating CF Growth per Share-7.35%
3-Year Operating CF Growth per Share-11.61%
10-Year Net Income Growth per Share86.07%
5-Year Net Income Growth per Share-1.13%
3-Year Net Income Growth per Share1.28%
10-Year Shareholders Equity Growth per Share-60.30%
5-Year Shareholders Equity Growth per Share-38.40%
3-Year Shareholders Equity Growth per Share-27.45%
10-Year Dividend per Share Growth per Share353.18%
5-Year Dividend per Share Growth per Share60.51%
3-Year Dividend per Share Growth per Share32.90%
Receivables Growth42.76%
Inventory Growth93.06%
Asset Growth49.19%
Book Value per Share Growth71.18%
Debt Growth65.91%
R&D Expense Growth7.89%
SGA Expenses Growth14.13%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 207,663,263,040, captures the company's total value, considering both debt and equity. Income quality, 1.26, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.20, gauges operational efficiency, while the research and development to revenue, 16.97%, highlights investment in innovation. The ratio of intangibles to total assets, 52.77%, indicates the value of non-physical assets, and capex to operating cash flow, -13.13%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value207,663,263,040
Income Quality1.26
Sales General and Administrative to Revenue0.20
Research and Development to Revenue16.97%
Intangibles to Total Assets52.77%
Capex to Operating Cash Flow-13.13%
Capex to Revenue-3.94%
Capex to Depreciation-27.32%
Stock-Based Compensation to Revenue1.53%
Graham Number57.36
Return on Tangible Assets14.64%
Graham Net Net-129.46
Working Capital11,940,000,000
Tangible Asset Value-45,038,000,000
Net Current Asset Value-60,590,000,000
Invested Capital10
Average Receivables6,752,500,000
Average Payables1,581,000,000
Average Inventory7,224,000,000
Days Sales Outstanding103
Days Payables Outstanding69
Days of Inventory On Hand411
ROIC9.53%
ROE1.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 26.69, and the price to book ratio, 26.69, reflect the market's valuation relative to the company's book value. The price to sales ratio, 5.92, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 22.67, and price to operating cash flows, 19.64, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio26.69
Price to Book Ratio26.69
Price to Sales Ratio5.92
Price Cash Flow Ratio19.64
Price Earnings to Growth Ratio-6.38
Enterprise Value Multiple9.34
Price Fair Value26.69
Price to Operating Cash Flow Ratio19.64
Price to Free Cash Flows Ratio22.67
Price to Tangible Book Ratio24.71
Enterprise Value to Sales7.37
Enterprise Value Over EBITDA14.03
EV to Operating Cash Flow24.51
Earnings Yield4.36%
Free Cash Flow Yield4.78%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Amgen Inc. (AMG.DE) on the XETRA in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 24.766 in 2024.

What is the ticker symbol of Amgen Inc. stock?

The ticker symbol of Amgen Inc. stock is AMG.DE.

What is company IPO date?

IPO date of Amgen Inc. is 2000-01-03.

What is company current share price?

Current share price is 259.800 EUR.

What is stock market cap today?

The market cap of stock today is 139231756200.000.

What is PEG ratio in 2024?

The current -6.375 is -6.375 in 2024.

What is the number of employees in 2024?

In 2024 the company has 26700.